Eli Lilly’s Groundbreaking Obesity Drug Yields 28% Weight Loss in Clinical Trial
Eli Lilly unveiled transformative results on Thursday, May 21, 2026, demonstrating that its innovative obesity drug, retatrutide, assisted patients in shedding over 28% of their body weight throughout an 80-week crucial late-stage clinical trial. This potentially sets it up as the most potent weight-loss medication on the market.
The maximum 12mg weekly injection dosage led to an average weight loss of 70.3 pounds. Remarkably, 45% of patients lost 30% or more of their body weight. These results are on par with those of bariatric surgery and significantly outshine current market leaders. Lilly’s Zepbound and Novo Nordisk’s Wegovy have demonstrated weight loss of approximately 15-20% in separate trials.
Known as the “triple G” drug, retatrutide operates differently from existing treatments. It targets three hormone receptors—GLP-1 to suppress appetite, GIP to enhance insulin secretion, and glucagon to aid fat burning—instead of just one or two. This multi-faceted approach seems to have stronger effects on appetite and food satisfaction than current blockbuster medications.
The pharmaceutical titan plans to seek FDA approval in 2027. This could revolutionize treatment options for the millions battling obesity. The results position Eli Lilly to maintain its competitive advantage in the thriving obesity treatment market, where it competes head-to-head with Denmark’s Novo Nordisk.
Source: CNBC